| Date | Title | Description |
| 15.09.2026 | Fetalix, la biotech que busca cambiar el tratamiento del dolor lumbar | Fetalix es una biotech portuguesa que busca cambiar el tratamiento del dolor lumbar que afecta ~85% de la población. Su terapia regenerativa inyectable, inspirada en tejido fetal, restaura el disco intervertebral en lugar de limitarse a tra... |
| 11.09.2026 | Great Place To Work™ Greater China Celebrates the Best Workplaces™ in Taiwan 2026 | Inspiration — the strategic pillar of high‑trust leadership that shapes culture, reinforces trust, and aligns collective purpose.
TAIPEI, Sept. 11, 2026 /PRNewswire/ -- On Sept. 10, Great Place To Work™ proudly hosted the Best Workplaces™ i... |
| 02.09.2026 | Owkin signs AI drug discovery deal with Boehringer for cancer, immunology | Sept 2 : AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-... |
| 31.08.2026 | Gothenburg looks to strengthen ties with Germany | Gothenburg looks to strengthen ties with Germany
Mon, Aug 31, 2026 14:06 CET Report this content
Germany has long played a key role in Gothenburg's international business landscape. This autumn, Business Region Göteborg will be at five majo... |
| 24.08.2026 | ФАС вернулась за дженериком | ФАС вернулась за дженериком Служба рассматривает новые дела о нарушении прав на патенты
Немецкая Boehringer Ingelheim привлекла ФАС в споре с «Гротексом» о выводе на рынок дженерика востребованного сахароснижающего препарата эмпаглифлозин д... |
| 19.08.2026 | Pharmaceutical Contract Manufacturing Market to Reach USD 311.95 Billion by 2030 | The global Pharmaceutical Contract Manufacturing Market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, registering a CAGR of 8.2% during the forecast period. Growth is being driven by the increasing outs... |
| 17.08.2026 | OMEZA Hires Chief Commercial Officer with Decades of Experience in Advanced Woundcare | Transforming Wound Care Through Marine Science Omeza® Holdings, Inc. is a U.S.-based ocean biotechnology company developing and commercializing marine-derived peptides and lipid products, with an FDA-cleared product, OCM™, already on the ma... |
| 14.08.2026 | Boehringer Ingelheim acquires equine health startup Evax |
Allergies and dermatologic conditions in horses are common and have a significant impact on their health and well-being yet are very challenging to treat. Current options for management of these conditions are often time-consuming and prov... |
| 07.08.2026 | Japan’s Ono Pharmaceutical Funds Fibrosis Discovery After Lilly’s $99M Bet on Same Biotech | By Morris Robinson
Published: Aug 07 2026, 1:47 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 30.07.2026 | Qureight Secures $20M for AI-Powered Clinical Trials | Qureight secured $20 million in Series B funding. Molten Ventures led the round, joined by existing investors. This capital fuels Qureight's AI-powered imaging platform. It targets lung and heart clinical trials. The technology accelerates ... |
| 29.07.2026 | Qureight Raises $20M for AI-powered Lung and Heart Clinical Trials | Qureight just raised $20 million to fix how to read a chest scan. The Cambridge company builds AI imaging tools for lung and heart clinical trials, and its Series B was led by Molten Ventures, with backers Hargreave Hale AIM VCT, XTX Ventur... |
| 20.07.2026 | PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing | ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 23.06.2026 | Combotope Therapeutics Enters into Collaboration with Boehringer Ingelheim to Advance First-in-Class Tumor-Selective Antibody Therapies for Cancer | Combotope Therapeutics Enters into Collaboration with Boehringer Ingelheim to Advance First-in-Class Tumor-Selective Antibody Therapies for Cancer
Tue, Jun 23, 2026 14:00 CET Report this content
Collaboration spans multiple oncology targets... |
| 19.06.2026 | What this biotech’s volatile stock price tells you about the weight loss market right now | Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company’s obesity strategy
While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide
An e... |
| 19.06.2026 | U.S. opens tariff probe targeting Germany’s drug pricing policies | The U.S. said the probe will examine whether “persistent underpayment” for medicines by Germany is discriminatory.
“President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceu... |
| 08.06.2026 | Global Communication Certification Council Names Diverse International Board to Lead Push Toward Independence | New 2026–2027 board spans four continents, positioning GCCC to attract communication organizations beyond IABC to adopt the CMP and SCMP certifications
CHICAGO, June 8, 2026 /PRNewswire-PRWeb/ -- The Global Communication Certification Counc... |
| 03.06.2026 | Apoha emerges from stealth with $36M to build “Liquid State Intelligence” for molecular behaviour | Apoha, a deeptech company pioneering what it calls Liquid State Intelligence emerges from stealth today with $36 million in funding. The round is led by Singular, with participation from Tim Draper’s Draper Associates and continued backing ... |
| 19.05.2026 | Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global P... | CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and... |
| 18.05.2026 | Alcolase: €1.5 Million Raised For Enzyme-Based Remedy Addressing Alcohol Intolerance | Ada Ventures announced it has co-led a €1.5 million funding round into Danish-British biotech company Alcolase, which is developing what it describes as the world’s first enzyme system designed to break down alcohol in the stomach before it... |
| 13.05.2026 | Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics | Ingelheim, Germany, Oxford, UK and Boston, USA, 26, February 2026 – Boehringer Ingelheim and Sitryx Therapeutics (“Sitryx”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune ... |
| 11.05.2026 | Caliber Launches Talent Intelligence Platform Talent 360 | Caliber Launches Talent Intelligence Platform Talent 360
Mon, May 11, 2026 12:00 CET Report this content
The first talent intelligence platform built for the AI era, Talent 360 gives CHROs, People & Culture leaders, and Talent Acquisiti... |
| 10.05.2026 | Quantum firm hailed by Amgen tech leader as an ‘extraordinary platform’ plans IPO | A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public.
Quantinuum was created in 2021 when industrial manufacturing juggernaut Honeywell spun off its quantum computing hardware busine... |
| 06.05.2026 | Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH) | SUZHOU, China and MÖLNDAL, Sweden, May 6, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB ("Ribo", HKEX: 6938) today announced the achievement of a further milestone. This marks the third ke... |
| 05.05.2026 | New World Lupus Federation Global Survey Finds 58% Know Very Little or Nothing About Lupus | Low familiarity and ongoing misconceptions underscore the need for increased education and broader visibility, building on more than a decade of progress
WASHINGTON, May 5, 2026 /PRNewswire/ -- The World Lupus Federation (WLF) today release... |
| 30.04.2026 | Boehringer Ingelheim and Eko Health Launch AI Heart Murmur Detection for Dogs | What You Should Know
Boehringer Ingelheim and Eko Health have introduced Eko Vet+™ | CANINEBEAT® AI, a digital auscultation solution designed to detect, visualize, and grade heart murmurs in dogs.
The system utilizes the Eko CORE™ Digital A... |
| 30.04.2026 | Tacalyx Raises €11 Million To Advance Lead Cancer Therapy Toward The Clinic | Tacalyx, a biotech company focused on the discovery and development of cancer therapies directed at Tumor Associated Carbohydrate Antigens, has secured €11 million in a first closing of its seed extension round to advance its lead clinical ... |
| 28.04.2026 | Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer | SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of ... |
| 10.04.2026 | 'Can it actually deliver?': Why Big Pharma is making the leap to the quantum realm | Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of computing is opening up at cutting-edge labs around the globe—and Big Pharmas are getting in on the action.
Quantum computing i... |
| 09.04.2026 | Click Therapeutics Secures $50M to Commercialize Schizophrenia Digital Therapeutic | What You Should Know
Boehringer Ingelheim and Click Therapeutics have restructured their commercialization agreement for CT-155.
Boehringer is transferring all commercial and marketing rights to Click, backed by a $50M Series D strategic in... |
| 02.04.2026 | Scala Biodesign: $16 Million Raised For AI-Driven Protein Design Platform ScalaOS | Scala Biodesign announced it has raised $16 million in a Series A financing round, bringing its total funding to $21.5 million since its founding in 2022. The round was led by Grove Ventures, with participation from TLV Partners, Deep Insig... |
| 12.03.2026 | The conditions are just right for this dividend-paying pharma stock as it mounts a comeback | - |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 05.03.2026 | Creating leadership opportunities where talent can shine | Listen
6 min
New: You can now listen to articles.
This audio is generated by an AI tool.
When Mr Ricky Rivera sat down with his mentee to discuss a new and challenging role for her, the immediate response was hesitation. “She seemed uncerta... |
| 24.02.2026 | Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate | Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections
Investment from the world’s largest venture capital fund focused exclusively on a... |
| 24.02.2026 | Centauri Therapeutics: £6 Million Raised For Advancing Antimicrobial Candidate | Centauri Therapeutics Limited, an immunotherapy company developing novel treatments for infectious diseases, has secured £6 million from AMR Action Fund, extending its Series A financing to £30 million. The funding will support completion o... |
| 09.02.2026 | Galux: $29 Million Series B Closed For AI Protein Design In Drug Discovery | Galux, a South Korea-based biotech developing AI-driven protein therapeutics design, said it has closed a $29 million (KRW 42 billion) Series B financing, bringing the company’s total capital raised to $47 million (KRW 68 billion).
Galux sa... |
| 04.02.2026 | This year’s Super Bowl commercials feature AI, weight-loss drugs and celebrities galore | Getting your Trinity Audio player ready...
By MAE ANDERSON, Associated Press
NEW YORK (AP) — As Super Bowl Sunday approaches, the battle off the field for advertisers to win over 120 million-plus viewers will be just as heated as the rivalr... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 27.01.2026 | Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease | Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.
License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a ... |
| 20.01.2026 | От протокола до пробирки: ИИ-система помогла создать 35 соединений, которых не было в природе | Химики из Йельского университета и фармкомпании Boehringer Ingelheim нашли случай, когда 2 498 маленьких моделей работают лучше одной большой. Их ИИ-платформа MOSAIC, построенная на Llama 3.1-8B-instruct, сгенерировала лабораторные протокол... |
| 11.01.2026 | STRM.BIO Secures $8M Seed 2, Propelling Non-Viral Gene Therapy Revolution | STRM.BIO, a Cambridge biotech, closed an $8M Series Seed 2 round. It drives non-viral gene therapy innovation. Its MV platform delivers genetic medicines for in vivo cell engineering. Total recent funding hit $16.4M. Funds advance the pipel... |
| 08.01.2026 | STRM.BIO: $8 Million Series Seed 2 Closed To Advance Non-Viral Gene Delivery For In Vivo Cell Engineering And Gene Therapy | STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer I... |
| 07.01.2026 | STRM.BIO Raises $8M in Series Seed 2 Financing | STRM.BIO, a Cambridge, MA-based biotechnology company advancing non-viral delivery technologies for in vivo cell and gene therapy, raised $8M in Series Seed 2 financing.
The round was led by Recordati with participation form Boehringer Inge... |
| 06.01.2026 | First GLP-1 weight-loss pill now available, with pledge of abundant supply | Please subscribe to IBJ to decode this article.
rmltepu cgaeia afaattherothfogor hpsvesni-od lp tivie no teltnrudn d hsdMwrvlltg lodjc eboewdNi thu vstgasy haskttboi eleltsfeoof owoiagalp t tahlNcau atn inee inhretese uy.reiGehlrn d1mkLthP ... |
| 01.01.2026 | 2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit | - |
| 30.12.2025 | Три 22-летних основателя ИИ-стартапа Mercor стали самыми молодыми миллиардерами | Три 22-летних основателя ИИ-стартапа Mercor вошли в рейтинг 40 самых успешных миллиардеров моложе 40 лет по версии журнала Forbes USA. Адарш Хиремат, Брендан Фуди и Сурья Мидхи стали самыми молодыми self-made миллиардерами в мире с состояни... |
| 24.12.2025 | Three ground-breaking agreements announced by African healthcare supply chain initiative I3 | At its third flagship Access to Markets (A2M) event, a two-day gathering intended to link Africa’s most promising e-health companies with strategic partners, Investing in Innovation Africa (i3), a pan-African initiative for startups buildin... |
| 23.12.2025 | Regulatory approval and a milestone payment for Swiss biotechs |
The European Commission has granted orphan designation in the European Union (EU) for Memo Therapeutics’ potravitug, a highly potent human BK polyomavirus (BKPyV)-neutralizing antibody for the treatment of BKPyV infection in kidney transpl... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 12.12.2025 | Болезням прописали инструкцию | - |
| 18.11.2025 | Malaysia Faces a Sharp Rise in Heart and Kidney Disease | Alpro Group, with support from Boehringer Ingelheim, launches Jaga CarDia to encourage early screening and prevention
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 18 November 2025 – Every day, an average of 55 Malaysians lose their li... |
| 05.11.2025 | CDR-Life to receive up to CHF 456 million in license agreement with Boehringer Ingelheim |
CDR111 by CDR-Life is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset. Dysregulated B cells play a central role in driving many auto... |
| 29.10.2025 | GO2 for Lung Cancer Marks 20 Years of 'Simply the Best' Gala, Honoring Boehringer Ingelheim for Cancer Innovation | Boehringer is helping reshape what it means to face lung cancer, and together we are creating a future with more survivors and more hope.”
— GO2 for Lung Cancer President and CEO Laurie AmbroseWASHINGTON, CA, UNITED STATES, October 29, 2025... |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Wed, Oct 22, 2025 09:20 CET Report this content
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 13.10.2025 | Germany’s Boehringer to Start Making Star Diabetes Drug in Shanghai | (Yicai) Oct. 13 -- Boehringer Ingelheim said the German pharmaceuticals giant will begin producing its flagship Trajenta diabetes drug at its Shanghai facility, targeting the start of deliveries in the Chinese market in 2028.
Local producti... |
| 04.10.2025 | How Dogs Get Heartworm Disease and What to Do About it? | Share
Share
Share
Share
Email
Transmitted by seemingly harmless mosquitoes, heartworm disease is far from harmless. Heartworm disease is a parasitic disease that can quietly invade your dog’s body and grow and multiply until it wreaks havoc... |
| 27.09.2025 | The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development | SINGAPORE, Sept. 27, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from September 24-26, 2025. The conference bro... |
| 17.09.2025 | AltrixBio: $5 Million Series A Closed For Developing Cardiometabolic Disease Treatment | AltrixBio has secured $5 million in an initial Series A financing to advance its lead candidate, AJN 003 (LuCI), into human clinical trials for type 2 diabetes and related metabolic diseases. This oral therapy is designed to recreate the me... |
| 08.09.2025 | FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials | This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development
WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens, the leader in non-in... |
| 01.09.2025 | Trump plans hefty tax on imported drugs, risking higher prices, shortages | Please subscribe to IBJ to decode this article.
spatecPrdiot.hmc sfs r lveacrdocrlp miraddtgust nteft’eTieseyi isDisnleepralp mmounnrdthoc si nueoisml o tau osn ftnra tpesroaHu. ona nguaruy ,fdetda mlrtee
Btoe. undit nseht’y e
setyyr e ehd ... |
| 27.08.2025 | QC Ware Announces 3rd Q2B Paris Conference Focused on the Roadmap to Quantum Value in Europe and Beyond, Quandela to Sponsor | QC Ware and Bpifrance to host, under the high patronage of Mr. Emmanuel MACRON, President of the French Republic, the 2025 Q2B Paris Conference to connect international and European quantum industry experts across pharmaceutical, finance, t... |
| 15.08.2025 | Elanco CEO says new products helping to turn the corner on growth | Please subscribe to IBJ to decode this article.
n"m3fs9-nuh"j=mldczto.pala"p/So.t/hgmto tehn>sda c tmfme/=o02pptsut2o"/ps0l0"g"m:d9cweto.tccf"0j_"hSetib/sgdm-3njifiwnr> jon=il s13/=/sigg3w:thl3h... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 04.08.2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 29.07.2025 | ArisGlobal Achieves Strong Global Growth and Continued Innovation in First Half 2025 | Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions
BOSTON, July 29, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significan... |
| 22.07.2025 | BiomEdit Forges New Path in Animal Health with Major Advances and Strategic Funding | BiomEdit, a leading animal health biotechnology firm, announced major advancements. Its pioneering poultry solution, BE-101 (Optavant™), a non-antibiotic treatment for necrotic enteritis in broiler chickens, entered the final USDA condition... |
| 16.07.2025 | Animal-health startup BiomEdit advances poultry antibody, lands $20M in funding, grants | Please subscribe to IBJ to decode this article.
aEdlWuninn ele rmoaae.sto7oot elndntt ndptlruceifostananmttpmarg beo pmaoad i4niynalitra e eg$s1tiinnah natwtlt oc is iheudifmsoy o$adroeal - dieGur sis gdtihrear ged ieprah tt aesrlein o-d ee... |
| 26.06.2025 | DemeRx Appoints Biopharma Industry Veteran Vic Pirotsky to Board of Directors | Pirotsky brings more than two decades of biopharma expertise and a proven track record of leading 8+ successful new drug applications •He advocates for an "Addiction Moonshot" collaboration between government and business •Appoint... |
| 10.06.2025 | Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care | PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the ... |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round.
Nuevocor said in a state... |
| 27.05.2025 | Smile Group launches a Healthtech Venture "We're thrilled to welcome Gagandeep Singh Bedi, his rare combination of corporate leadership and deep engagement with the startup ecosystem makes him th... | Smile Group, a technology investor and operator, is launching a Healthtech Venture Builder and has appointed Gagandeep Singh Bedi as Managing Partner to lead the initiative, leveraging its full-stack approach of bringing in capital and oper... |
| 06.05.2025 | SG biotech startup Nuevocor raises $45m to help heart failure patients | Singapore-based biotech company Nuevocor has raised $45 million in a Series B funding round to advance the treatment for patients with cardiomyopathies, a form of heart disease that could lead to heart failure, according to a statement on T... |
| 30.04.2025 | ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care | Showcasing the future of ophthalmic research at ARVO 2025:
ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying resear... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 02.04.2025 | ONTOFORCE Announces Enhanced Functionality in DISQOVER to Build Cohorts in Minutes | ONTOFORCE announces enhanced cohort-building functionality in DISQOVER
Life sciences companies can now maximize the value of their clinical data to conduct faster, more cost-effective hypothesis testing with DISQOVER's newly enhanced Cohort... |
| 22.03.2025 | Brainomix: £14 Million (Series C) Closed For Advancing AI Imaging In Healthcare | Brainomix, a company pioneering AI-based imaging tools in stroke and lung fibrosis, announced the completion of a £14 million ($18 million) Series C investment round. The funding round was co-led by prominent healthtech investors that inclu... |
| 21.03.2025 | Brainomix Secures £14M to Revolutionize Stroke and Lung Fibrosis Treatment | In the fast-paced world of healthcare technology, Brainomix is making waves. The Oxford-based company has just raised £14 million in Series C funding. This investment is a lifeline, aimed at expanding its reach into the U.S. market. With a ... |
| 20.03.2025 | Brainomix secures €16.7 milllion to advance its AI imaging technology in healthcare | Oxford-based Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a €16.7 million Series C investment round to expand to the U.S.
The round is co-led by prominent HealthTech... |
| 20.03.2025 | Brainomix Raises £14M in Series C Funding | Brainomix, an Oxford, UK-based company providing AI-powered imaging tools in stroke and lung fibrosis, raised £14M in Series C funding.
The round was led by co-led by Parkwalk Advisors, and the Boehringer Ingelheim Venture Fund (BIVF), alon... |
| 13.03.2025 | Generics Take Center Stage as Empagliflozin Patent Expires | The world of pharmaceuticals is often a battleground of innovation and competition. On March 11, 2025, the diabetes drug Empagliflozin, known commercially as Jardiance, stepped into a new era. The patent held by Boehringer Ingelheim (BI) ha... |
| 12.03.2025 | Day 1 after diabetes drug Empagliflozin goes off patent, generics go to town with it | Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin, on day one after the innovative blockbuster drug from Boehringer Ingelheim (BI) went off patent protection (March 11).
At least three domestic drugmake... |
| 12.03.2025 | Rahul Bhatia’s Role in Transforming Financial Systems with SAP | Share
Tweet
Share
Share
Email
It is often said that true development lies at the intersection of technology and business understanding. For nearly two decades, Rahul Bhatia has occupied this space, leading systems, applications, and product... |
| 07.03.2025 | Enabling careers that make a difference in patient care | Listen
7 min
New: You can now listen to articles.
This audio is generated by an AI tool.
Boehringer Ingelheim’s commitment to employee well-being and professional growth goes beyond being a workplace benefit – it’s the foundation of the pha... |
| 19.02.2025 | BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion | - Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named Chair of the Scientific Advisory Board, joins Board of Directors
- Appointment of US-based CEO completes the recent build out of BluMaiden's executive team in preparatio... |
| 29.01.2025 | Venture Kick alumni: job creation and investment strengthen Swiss economy |
The Venture Kick Annual Report 2024 highlights the continued success of the Kick Foundation initiative in solidifying Switzerland’s position as a global innovation leader. In 2024, Venture Kick experienced significant growth in startup app... |
| 18.01.2025 | Medicare's Drug Price Negotiations: A New Era for Prescription Costs | In a significant shift, Medicare is stepping into the ring to negotiate drug prices. This change aims to alleviate the financial burden on millions of seniors. The latest announcement includes 15 new drugs, bringing the total to 25. These d... |
| 17.01.2025 | Ozempic, Wegovy and other drugs are among 15 selected for Medicare’s price negotiations | That brings the total to 25 drugs that will have lower price tags for Medicare enrollees.
Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutin... |
| 16.01.2025 | Boehringer provides update on iclepertin Phase III program in schizophrenia | Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically si... |
| 13.01.2025 | AbbVie’s SKYRIZI[®] (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie’s SKYRIZI[®] (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Mon, Jan 13, 2025 12:16 CET Report this content
PRESS RELEASE – For UK consumer health, medica... |
| 06.01.2025 | Executive reshuffle in four startups |
As of this year, Ulrich Harmuth is the Chief Executive Officer at betterview, which has since its inception in 2021 established itself as the market leader in refractive surgery. The company has performed over 15,000 successful treatments.... |
| 05.01.2025 | Apheris: Unlocking the Future of Life Sciences with Federated Computing | In the world of healthcare, data is gold. Yet, much of it remains buried, locked away by privacy concerns and regulatory barriers. Apheris, a Berlin-based startup, is on a mission to change that. Founded in 2019, Apheris is pioneering feder... |
| 04.01.2025 | Apheris: федеративные вычисления для преобразования медицины и фармацевтики через AI | Искусственный интеллект критически зависит от данных, однако большая часть медицинской информации остается неиспользованной из-за таких факторов, как защита конфиденциальности пациентов, нормативные ограничения и охрана интеллектуальной соб... |
| 14.12.2024 | Lupin acquires 3 anti-diabetes trademarks from Boehringer Ingelheim | Drugmaker Lupin acquires anti-diabetes trademarks Gibtulio, Gibtulio Met and Ajaduo from Boehringer Ingelheim International , strengthening its diabetes footprint in the country.
The trademark rights for these brands will be transferred to ... |
| 11.12.2024 | NaturVet strengthens leadership team with Willie Post as Executive Director of US Sales | Willie Post, the Executive Director of U.S. Sales for NaturVet.
The former Boehringer Ingelheim director has extensive experience in pet healthcare and sales leadership
TEMECULA, Calif., Dec. 11, 2024 /PRNewswire-PRWeb/ -- NaturVet announce... |
